

PE/Cyanine7 anti-human CD365 (Tim-1)

Catalog # / Size: 2369545 / 25 tests
2369550 / 100 tests

Clone: 1D12

Isotype: Mouse IgG1, κ

Immunogen: Human TIM-1-IgV Fc


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Cyanine7 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

Workshop Number: HCDM listed

Concentration: Lot-specific



769-P, human kidney cell line was stained with anti-human CD365 (Tim-1) (clone 1D12) PE/Cyanine7 (filled histogram) or mouse IgG1, κ PE/Cyanine7 isotype control (open histogram)

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μL per million cells in 100 μL staining volume or 5 μL per 100 μL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported application (for the relevant formats) include: blocking function¹.

Application References: 1. Freeman GJ, *et al.* 2007. *Immunity*. 27:927. (Block)

Description: CD365 (Tim-1) is a transmembrane glycoprotein expressed on activated CD4⁺ lymphocytes especially on Th2 cells. It has been implicated to play a critical role in the development of atopic disease and other Th2-biased immune responses. Tim-1 is a hepatitis A virus receptor in humans. Tim-4 is the endogenous ligand of Tim-1. The interaction of Tim-1 and Tim-4 is involved in the costimulation of T cell proliferation. Tim-1 has been reported to be an endogenous ligand for LMIR5 (Leukocyte mono-immunoglobulin (Ig)-like receptor 5), and the Tim-1-LMIR5 interaction plays a physiological role in immune regulation by myeloid cells.

Antigen References: 1. Freeman GJ, *et al.* 2007. *Immunity*. 27:927.
2. Meyers JH, *et al.* 2005. *Nat. Immunol.* 6:455.
3. Kuchroo VK, *et al.* 2003. *Nat. Rev. Immunol.* 3:454.
4. Mariat C, *et al.* 2005. *Philos. Trans. R. Soc. Lond. B.* 360:1681.
5. Yamanishi Y, *et al.* 2010. *J. Exp. Med.* 207:1501.